Fu Shijie, Du Haizhen, Dai Yuyang, Zheng Kanglian, Cao Guang, Xu Liang, Zhong Yujie, Niu Chuanxin, Kong Yan, Wang Xiaodong
Department of Interventional Radiology, Beijing Friendship Hospital, Capital Medical University, Beijing 100000, China.
Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital and Institute, Beijing 100142, China.
iScience. 2024 Dec 4;27(12):111437. doi: 10.1016/j.isci.2024.111437. eCollection 2024 Dec 20.
The efficacy of hepatic arterial infusion chemotherapy (HAIC) with oxaliplatin (OXA) and 5-fluorouracil (5-Fu) for treating advanced perihilar cholangiocarcinoma (pCCA) has been demonstrated, yet the survival benefits of HAIC for pCCA patients vary. Here, we aimed to screen out HAIC resistance-related bile microRNAs (miRNAs) and explore the functions of specific bile miRNAs in pCCA based on high-throughput sequencing. Levels of bile miR-532-3p, miR-1250-5p, and miR-4772-5p were related to the survival of advanced pCCA patients after HAIC. However, only overexpression of miR-532-3p promoted OXA/5-Fu resistance, and downregulation of its expression improved sensitivity to OXA/5-Fu. Mechanistic investigations revealed secreted protein acidic and rich in cysteine (SPARC) as the direct target of miR-532-3p. Our study reveals that bile miR-532-3p, miR-1250-5p, and miR-4772-5p may serve as survival biomarkers in advanced pCCA patients after HAIC and that bile miR-532-3p promotes resistance to HAIC with OXA and 5-Fu via negatively regulating SPARC expression.
肝动脉灌注化疗(HAIC)联合奥沙利铂(OXA)和5-氟尿嘧啶(5-Fu)治疗晚期肝门部胆管癌(pCCA)的疗效已得到证实,但HAIC对pCCA患者的生存获益存在差异。在此,我们旨在基于高通量测序筛选出与HAIC耐药相关的胆汁微小RNA(miRNA),并探索特定胆汁miRNA在pCCA中的功能。胆汁miR-532-3p、miR-1250-5p和miR-4772-5p的水平与晚期pCCA患者接受HAIC后的生存相关。然而,只有miR-532-3p的过表达促进了OXA/5-Fu耐药,而其表达下调则提高了对OXA/5-Fu的敏感性。机制研究表明,富含半胱氨酸的酸性分泌蛋白(SPARC)是miR-532-3p的直接靶点。我们的研究表明,胆汁miR-532-3p、miR-1250-5p和miR-4772-5p可能作为晚期pCCA患者接受HAIC后的生存生物标志物,并且胆汁miR-532-3p通过负向调节SPARC表达促进对OXA和5-Fu的HAIC耐药。